Mirati Therapeutics Inc.
Clinical trials sponsored by Mirati Therapeutics Inc., explained in plain language.
-
Cancer patients get extended access to experimental drug after showing benefit
Disease control CompletedThis study allowed patients with advanced cancers who were already benefiting from sitravatinib in a previous trial to continue receiving the drug. It monitored the safety and side effects of continued treatment with sitravatinib, either alone or combined with other cancer therap…
Phase: PHASE2, PHASE3 • Sponsor: Mirati Therapeutics Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New hope for Tough-to-Treat lung cancer: trial tests combo to overcome treatment resistance
Disease control CompletedThis study tested whether adding an investigational pill called sitravatinib to an immunotherapy drug (nivolumab) works better than standard chemotherapy (docetaxel) for people with advanced non-squamous lung cancer. It involved 577 patients whose cancer had worsened despite rece…
Phase: PHASE3 • Sponsor: Mirati Therapeutics Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:10 UTC